URB2 and central nervous system cancer: To further assess the diagnostic ability of URB2, we conducted a receiver operating characteristic (ROC) curve analysis, and the area under the curve (AUC) was 0.592 (1-year), 0.658 (3-year), and 0.6790 (5-year), respectively, indicating a low efficacy in diagnosing glioma based on the expression of URB2 (Figure 1H).